Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers-Reference-Cited by-同舟云学术

Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers

Published:2013-05 Issue:4 Volume:45 Page:1603-1607
ISSN:0041-1345
Container-title:Transplantation Proceedings
language:en
Short-container-title:Transplantation Proceedings

Author:

Alain S.,Revest M.,Veyer D.,Essig M.,Rerolles J.P.,Rawlinson W.,Mengelle C.,Huynh A.,Kamar N.,Garrigue I.,Kaminski H.,Segard C.,Presne C.,Mazeron M.C.,Avettant-Fenoël V.,Lecuit M.,Lortholary O.,Coaquette A.,Hantz S.,Leruez-Ville M.,Ploy M.-C.

Publisher

Elsevier BV

Subject

Transplantation,Surgery

Reference15 articles.

1. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study;Hantz;J Antimicrob Chemother,2010

2. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis;Boivin;J Med Virol,2005

3. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir;Boivin;Antivir Ther,2009

4. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes;Eid;Clin Transplant,2008

5. Maribavir (ViroPharma);Lu;Curr Opin Investig Drugs,2004

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature;Transplantation Reviews;2024-12

2. Efficacy of the drug maribavir according to clinical studies;Clinical Medicine (Russian Journal);2024-05-07

3. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12

4. New Perspectives on Antimicrobial Agents: Maribavir;Antimicrobial Agents and Chemotherapy;2022-09-20

5. Le complexe terminase, une cible de choix dans le traitement de l’infection à cytomégalovirus humain;médecine/sciences;2020-04